In addition, entrectinib, which is a TRK receptor kinase inhibitor indicated for NTRK fusion‐positive tumors, is also a potent inhibitor of ROS1, enabling it to be approved for ROS1‐positive NSCLC.193, 194, 472. Here, ROS1 is linked to non-small cell lung carcinoma.